Amplio Pharma initiates Series A financing of approximately €10 million to advance NovoBioJect, a next-generation rheumatoid arthritis treatment, into Phase 2a trials.
Amplio Pharma has reported positive early clinical results for NovoBioJect, designed to improve treatment for rheumatoid arthritis. They are initiating a Series A financing round of approximately €10 million to fund further development. The recent study demonstrates a significant increase in the active form of methotrexate in patients. This funding will support the next phase of clinical testing for NovoBioJect.
Company Information
Company
Amplio Pharma
Location
Amsterdam, North Holland, Netherlands
About
Amplio Pharma is a clinical-stage pharmaceutical company focused on developing NovoBioJect to enhance the first-line treatment of rheumatoid arthritis (RA). Their innovative approach combines low-dose methotrexate with novobiocin to improve drug retention in immune cells. This aims to offer a potential next-generation treatment for patients who do not achieve remission with standard therapies. Amplio's research is supported by positive early clinical trial results demonstrating significant improvements in drug accumulation.
Fundz sees it the moment Amplio Pharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
AmsterdamBiotechnologyHealth CareMedicalTherapeuticsPharmaceutical